Robust growth of avirulent phase II \textit{Coxiella burnetii} in bone marrow-derived murine macrophages

Diane C. Cockrell\(^1\), Carrie M. Long\(^1\), Shelly J. Robertson\(^2\), Jeffrey G. Shannon\(^3\), Heather E. Miller\(^1\), Lara Myers\(^4\), Charles L. Larson\(^1\), Tregei Starr\(^5\), Paul A. Beare\(^1\), Robert A. Heinzen\(^1\)*

\(^1\) \textit{Coxiella} Pathogenesis Section, Laboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America, \(^2\) Innate Immunity and Pathogenesis Unit, Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America, \(^3\) Plague Section, Laboratory of Zoonotic Pathogens, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America, \(^4\) Retroviral Immunology Section, Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America, \(^5\) \textit{Salmonella}-Host Cell Interactions Section, Laboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America

* rheinzen@niaid.nih.gov

Abstract

Published data show that murine bone marrow-derived macrophages (BMDM) restrict growth of avirulent phase II, but not virulent phase I, \textit{Coxiella burnetii}. Growth restriction of phase II bacteria is thought to result from potentiated recognition of pathogen-associated molecular patterns, which leads to production of inhibitory effector molecules. Past studies have used conditioned medium from L-929 murine fibroblasts as a source of macrophage-colony stimulating factor (M-CSF) to promote differentiation of bone marrow-derived myeloid precursors into macrophages. However, uncharacterized components of conditioned medium, such as variable amounts of type I interferons, can affect macrophage activation status and their permissiveness for infection. In the current study, we show that the \textit{C. burnetii} Nine Mile phase II (NMII) strain grows robustly in primary macrophages from C57BL/6J mice when bone marrow cells are differentiated with recombinant murine M-CSF (rM-CSF). Bacteria were readily internalized by BMDM, and replicated within degradative, LAMP1-positive vacuoles to achieve roughly 3 logs of growth over 6 days. Uninfected BMDM did not appreciably express CD38 or Egr2, markers of classically (M1) and alternatively (M2) activated macrophages, respectively, nor did infection change the lack of polarization. In accordance with an M0 phenotype, infected BMDM produced moderate amounts of TNF and nitric oxide. Similar NMII growth results were obtained using C57BL/6J myeloid progenitors immortalized with an estrogen-regulated \textit{Hoxb8} (\textit{ER-Hoxb8}) oncogene. To demonstrate the utility of the ER-Hoxb8 system, myeloid progenitors from natural resistance-associated macrophage protein 1 (Nramp1) C57BL/6J knock-in mice were transduced with \textit{ER-Hoxb8}, and macrophages were derived from immortalized progenitors using...
rmM-CSF and infected with NMII. No difference in growth was observed when compared to macrophages from wild type mice, indicating depletion of metal ions by the Nramp1 transporter does not negatively impact NMII growth. Results with NMII were recapitulated in primary macrophages where C57BL/6J Nramp1+ BMDM efficiently killed Salmonella enterica serovar Typhimurium. M-CSF differentiated murine macrophages from bone marrow and conditional ER-Hoxb8 myeloid progenitors will be useful ex vivo models for studying Coxiella-macrophage interactions.

Introduction

Coxiella burnetii is the bacterial cause of human Q fever, an aerosol-transmitted zoonotic infection [1]. This intracellular pathogen has a low human infective dose (~10 microorganisms) and initially targets alveolar macrophages during natural infection [2]. Following receptor-mediated uptake, the nascent C. burnetii-containing vacuole (CCV) traffics through the canonical endolysosomal pathway to acquire characteristics of a degradative phagolysosome [3]. The mature CCV supporting pathogen replication is a specialized compartment that engages autophagic, endocytic, and secretory pathways [4]. CCV biogenesis and successful infection requires manipulation of several host cell functions by effector proteins secreted by a specialized Dot/Icm type IV secretion system (T4BSS) [4].

Central to C. burnetii pathogenesis is resistance to, or avoidance of, macrophage innate immune responses. Inhibitory components of innate immunity include reactive nitrogen intermediates and oxygen species, antimicrobial peptides, nutrient limitation, autophagy, and programmed cell death [5, 6]. The antagonistic effects of several of these factors/processes are associated with fusion of lysosomes with compartmentalized bacteria, a process promoted by autophagic machinery [7]. However, C. burnetii is naturally resistant to lysosomal activities of resting macrophages. In fact, the T4BSS of C. burnetii mediates interactions between the CCV and the autophagy pathway that appear to benefit CCV formation and/or pathogen growth [8–11]. Infection also renders host cells resistant to inducers of apoptosis and pyroptosis, with four C. burnetii T4BSS effector proteins known to exert pro-survival effects [12–14].

Induction of cell autonomous innate immune functions requires detection of bacterial pathogen-associated molecular patterns (PAMPs) by pathogen-recognition receptors (PRR) [15]. Toll-like receptors (TLR) of the plasma membrane primarily detect bacterial surface PAMPs while cytosolic PRRs detect PAMPs released into the cytoplasm. Typically, PAMP recognition results in classically (M1) activated macrophages with pro-inflammatory properties that thwart invading bacterial pathogens [16, 17]. However, some pathogens are adept at preventing M1 polarization or promoting polarization of alternatively (M2) activated macrophages, which are considered anti-inflammatory [17].

The degree and outcome of PRR signaling triggered by C. burnetii infection primarily depends on lipopolysaccharide (LPS) length [18, 19]. Natural isolates of C. burnetii that produce a full-length LPS undergo a serologically-defined phase I (virulent) to phase II (avirulent) transition after extensive in vitro passage. Phase II bacteria produce a severely truncated LPS containing lipid A and some core sugars, but no O-antigen [20–22]. Interactions between isogenic C. burnetii Nine Mile phase I (NMI) and phase II (NMII) reference strains and cultured myeloid cells have been extensively characterized [23]. The O-antigen of NMI appears to mask the outer membrane and limit recognition of surface PAMPs, such as lipoproteins [18, 19, 24]. Consequently, relative to in vitro infection by NMII, NMI induces a limited pro-inflammatory
response. NMI and NMII produce an identical tetra-acylated lipid A that weakly interacts with TLR 4 [25].

Induction of a potentiated innate immune response by NMII is considered an important mechanism that clears the organism from an immunocompetent animal in the absence of disease [19, 26, 27]. Relative to NMI, in vitro infection of primary human myeloid cells by NMII results in production of more pro-inflammatory cytokines, such as tumor necrosis factor (TNF), interleukin-12p70 (IL-12p70) and interleukin-1ß (IL-1ß), but ultimately both strains replicate similarly [3, 19, 28]. In contrast, the robust pro-inflammatory response observed upon NMII infection of murine primary bone marrow-derived macrophages (BMDM) is associated with moderate to severe growth restriction, depending on the mouse strain [25, 27, 29–35]. For example, BMDM from A/J and Balb/c mice are moderately permissive for NMII growth while macrophages from C57BL/6 are highly restrictive [30]. A recent comprehensive study of NMII engagement of the innate immune response of C57BL/6 BMDM confirmed the importance of TLR2 in inhibiting NMII growth through production of TNF [27]. No role for cytosolic PRRs was established [27]. These results are in accordance with previous studies showing BMDM from TLR2 knockout mice are markedly more permissive for growth of NMII than wild type macrophages [25], and that the corresponding knockout mouse is more susceptible to NMII infection [36]. Nitric oxide appears to be a key inhibitory effector induced by TNF [27]. Indeed, nitric oxide has been previously shown to inhibit NMII replication in murine L-929 fibroblasts [37] and BMDM [31, 32].

To our knowledge, conditioned medium from murine L-929 cell cultures has been used in published NMII infection studies as the source of macrophage-colony stimulating factor (M-CSF) for differentiation of bone marrow-derived myeloid progenitors into macrophages [25, 27, 29–35]. Here, we demonstrate that BMDM from C57BL/6 mice are highly permissive for growth of NMII when myeloid progenitor cells are differentiated with recombinant murine M-CSF (rmM-CSF). Bacteria achieve 2 to 3 logs of growth over 6 days in phagolysosome-like vacuoles. Both infected and uninfected BMDM lacked defined M1/M2 polarization, and infection resulted in production of moderate amounts of TNF and nitric oxide. Similar robust growth was also observed in macrophages obtained from wild type and natural resistance-associated macrophage protein 1 (Nramp1) knock-in C57BL/6J mice, where macrophages were derived from myeloid progenitors immortalized with an estrogen-regulated Hoxb8 (ER-Hoxb8) oncogene. Collectively, our results show that primary and immortalized macrophages from C57BL/6J mice can be used to define host and bacterial determinants involved in productive infection of murine macrophages by avirulent phase II C. burnetii.

**Materials and methods**

**Bacteria**

*C. burnetii* Nine Mile RSA439 (phase II, clone 4) was utilized throughout this work and was grown microaerobically in ACCM-2 as previously described [38]. *Salmonella enterica* serovar Typhimurium strain SL1344 was grown in Luria-Bertani (LB) Miller media plus streptomycin (100 μg/ml) at 37°C with aeration at 225 rpm [39].

**Culture and infection of BMDM**

BMDM from C57BL/6J mice were generated as described by Crane et al. [40] with minor modifications. Female 8 to 12-week old C57BL/6J mice were sacrificed by deep anesthesia with isoflurane followed by cervical dislocation. Progenitor cells were isolated from femurs and tibia, and cultured in Dulbecco’s modified Eagle’s Medium (DMEM) + GlutaMAX (Gibco) containing 10% heat-inactivated fetal bovine serum (FBS), 1 mM sodium pyruvate (Corning),
20 ng/ml rmM-CSF (Peprotech), and penicillin/streptomycin (pen/strep) (Thermo Fisher Scientific) in 75-cm² flasks. After 2 days of incubation at 37°C in 5% CO₂, non-adherent cells were collected and sub-cultured with fresh medium lacking pen/strep (BMDM growth medium) into new 75-cm² flasks. Adherent cells were collected after 4 days and replated in 24 or 6-well plates in fresh medium containing rmM-CSF. Cells were cultivated overnight for respective experiments as detailed below. For infection, the medium was removed and the cells infected with NMI at the desired multiplicity of infection (MOI), based on genome equivalents, in a volume of 250 μl (24-well plates) or 2 ml (6-well plates) BMDM growth medium. Plates were centrifuged at 500 x g for 25 min at 37°C. BMDM were washed twice with 1 ml phosphate-buffered saline (PBS; 1.5 mM KH₂PO₄, 2.7 mM Na₂HPO₄·7H₂O, 155.0 mM NaCl, pH 7.2), and then 1 ml of BMDM growth medium was added to each well. For differentiation with L-929 cell-conditioned medium, rmM-CSF was replaced with 10% conditioned medium in BMDM growth medium.

Generation of ER-Hoxb8 progenitor cell lines

Myeloid progenitors from C57BL/6/J and C57BL/6/J Nramp1⁺ mice [41] were conditionally immortalized with an estrogen-regulated Hoxb8 (ER-Hoxb8) oncogene [42]. To generate retrovirus expressing the ER-Hoxb8 fusion, pHA-Hoxb8-MSCV-Neo and pEcoPac (both generously provided by Mark Kamps, University of California-San Diego) were co-transfected into 293T human kidney cells (ATCC CRL-3216) using a CaPO₄ transfection kit (Invitrogen) as described [42]. Transfected cells were cultured in DMEM + GlutaMAX, 10% FBS, and pen/strep (Thermo Fisher Scientific) at 37°C in 5% CO₂. Culture supernatants containing packaged retrovirus were harvested at 3 and 4 days post-transfection and stored at -80°C. Titers of retrovirus stocks were determined by infecting NIH3T3 murine fibroblasts (ATCC CRL-1658) with 10-fold dilutions of virus and quantifying the number of neomycin-resistant colony forming units observed after 2 weeks of culture in the presence of 1 mg/ml geneticin (Thermo Fisher Scientific).

Immortalized macrophage progenitor cells were generated as described by Wang et al. [42]. Briefly, bone marrow was harvested from mouse femurs and myeloid progenitor cells enriched using a mouse hematopoietic Progenitor Cell Isolation Kit (StemCell Technologies, Vancouver, British Columbia). Progenitor cells were cultured in stem cell medium (RPMI + GlutaMAX, 15% FBS, pen/strep [Thermo Fisher Scientific], 10 ng/ml murine IL-3, 20 ng/ml murine IL-6, and 30 ng/ml murine stem cell factor [Peprotech]) at 37°C in 5% CO₂. After 4 days of incubation, expanded progenitor cells (2.5 x 10⁵) were added to 250 μl of stem cell medium with Lipofectamine (Thermo Fisher Scientific), then mixed with 1 ml of Hoxb8-ER retrovirus (>2 x 10⁶ colony forming units per ml) in wells of a fibronectin-coated 12-well tissue culture plate. Plates were centrifuged for 90 min at 1,500 x g, then 3 ml of Mac-Pro medium (RPMI + GlutaMAX, 10% FBS, pen/strep, 20 ng/ml murine granulocyte-macrophage colony-stimulating factor [GM-CSF, Peprotech], 30 μM beta-mercaptoethanol, and 1 μM beta-estradiol [Sigma]) were added to each well and the plate was incubated at 37°C in 5% CO₂. Non-adherent cells were split into fresh Mac-Pro Medium every 3 to 4 days. By 2 weeks post-transduction, round macrophage progenitor cells in non-adherent or loosely adherent clusters were proliferating in wells, whereas no viable cells were found in non-transduced control wells.

Differentiation of progenitor cell lines into macrophages

Non-adherent ER-Hoxb8 progenitor cells were harvested by centrifugation and washed twice with PBS to remove beta-estradiol. The cells were then resuspended in Mac-Diff medium (RPMI + GlutaMax, 10% FBS, and 20 ng/ml rmM-CSF without beta-estradiol), seeded in
75-cm² flasks, and cultured for 6 days at 37°C in 5% CO₂. Cells were harvested by replacing the medium with cold PBS, chilling the flask on ice for 20 to 30 min, gently scraping the flask with a sterile cell scraper (Corning), and then centrifuging the cells for 5 min at 500 x g. Macrophages were seeded in a 24-well plate (2 x 10⁵ cells per well) in Mac-Diff medium for infection studies.

**Quantification of NMII growth and Salmonella survival**

Macrophages in 24-well plates (2 x 10⁵ cells per well) were infected with *C. burnetii* as described above. To harvest cells for quantitative PCR (qPCR), cells were scraped into growth medium and the suspension transferred to a 1.5 ml centrifuge tube. Wells were washed with 250 μl PBS, which was added to the centrifuge tube. Cells were harvested daily with the sample taken immediately after infection considered 0 days post-infection. Cells and bacteria were pelleted by centrifugation at 20,000 x g for 15 min. Supernatants were aspirated and pellets stored at -20°C until processing for qPCR of NMII genome equivalents (GE). Pellets were suspended in 200 μl of nuclease-free water and the suspension transferred to a 2 ml tube containing approximately 50 μl of 0.1 mm Zirconia/silica beads (BioSpec). Two cycles of bead beating were performed on each sample at a power of 5 for 40 sec using a ThermoElectron FastPrep FP120. Samples were heated at 99°C for 10 min and subjected to TaqMan qPCR using a StepOnePlus Real-Time PCR system (Applied Biosystems) to determine the copy number of *C. burnetii dotA* [43].

For infection of macrophages with *Salmonella* Typhimurium, bacteria were grown for 18 h to stationary phase. BMDM in 24-well plates (2 x 10⁵ cells per well) were infected at an MOI of 5 by centrifuging bacteria, suspended in 500 μl of BMDM growth medium, onto monolayers at 1000 x g for 10 min. At 30 min post-infection, the cells were washed once with PBS and BMDM growth medium with gentamicin (50 μg/ml) was added to each well. Media was replaced at 1.5 h post-infection with media containing 10 μg/ml gentamicin. Incubations were conducted at 37°C in 5% CO₂ and media was prewarmed to 37°C prior to use. Colony-forming units (CFUs) were collected at 1, 2, and 10 h post-infection following lysis of macrophages with 0.2% sodium deoxycholate in PBS. Serial dilutions were made and plated on LB-agar plates.

**Flow cytometry**

BMDM (6 x 10⁵ cells per well) in 6-well plates were infected as above with NMII at an MOI of 10 or left uninfected. At 56 h post-infection, cells were mock treated or treated with 100 ng/ml *Escherichia coli* 0111:B4 lipopolysaccharide (LPS; Sigma) or 20 ng/ml murine IL4 (R & D Systems). Six h prior to treatment with LPS, cells were also treated with 20 ng/ml murine IFNγ (R & D Systems). At 72 h post-infection, cells were pooled based on treatment and a minimum of 5 x 10⁵ cells was aliquoted into a 96-well round bottom plate or polystyrene tubes. Cells were washed and suspended in serum-free PBS, then stained with Fixable Viability Dye eFluor 780 according to the manufacturer’s protocol (eBioscience). Cells were suspended in staining buffer (PBS + 2% FBS) containing anti-mouse CD16/32 antibody (Clone 2.4G2; BD Biosciences) for blocking of Fc receptors to minimize nonspecific binding. Cells were then suspended in staining buffer containing a cocktail of fluorochrome-conjugated antibodies specific for cell surface antigens including: CD11b (Manufacturer: eBioscience, Clone: M1/70, Fluorophore: eFluor 450), F4/80 (eBioscience, BM8, Brilliant Violet 605), and CD38 (eBioscience, 90, Phycoerythrin). Following surface staining, cells were washed in staining buffer and fixed using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Following fixation, cells were permeabilized using the Foxp3/Transcription Factor Staining Buffer
Set and suspended in permeabilization buffer containing a cocktail of fluorochrome-conjugated antibodies specific for intracellular antigens including: Egr2 (eBioscience, erongr2, Allophycocyanin) and NMII (generated in-house, rabbit anti-NMII, unconjugated). Cells were washed in permeabilization buffer and suspended in this buffer containing goat anti-rabbit Alexa Fluor 488 IgG (Thermo Fisher Scientific) to stain NMII. Following intracellular staining, cells were suspended in staining buffer and analyzed on an LSR II flow cytometer using FACSDiva software (BD Biosciences). A minimum of 5 x 10^4 events was captured for each sample.

Following gating of all cells (FSC-A/SSC-A), live macrophages (Fixable Viability Dye eFluor 780) were first identified by their expression of CD11b and F4/80, then infected cells were identified based on NMII signal. M1 and M2 polarized subsets were identified based on CD38 and Egr2 expression, respectively [16, 44]. Isotype staining controls were included to help set gating boundaries and to ensure specificity of staining. Data analysis was performed with FlowJo v10.1 software (TreeStar Inc., Ashland, OR).

**Nitrite and TNF measurements**

BMDM (2 x 10^5 cells per well) in 24-well plates were infected with NMII at an MOI of 50. At 8 h post-infection, cells were mock treated or treated with 100 ng/ml LPS or 10 μg/ml zymosan (Sigma). For nitrite measurements, cells were also treated with 10 ng/ml murine TNF (PeproTech). At 24 h post-infection, culture supernatants were assayed for the relative level of nitric oxide by determining nitrite concentration with a Griess Reagent System (Promega). Culture supernatants stored at -20°C were assayed for TNF concentrations using a TNF ELISA kit (R & D Systems).

**Confocal fluorescence microscopy**

Primary BMDM and ER-Hoxb8 macrophages (2 x 10^5 cells per well) seeded on 12-mm cover-slips in a 24-well plate were infected with NMII at an MOI of 10 and incubated for the indicated times. For NMII, LAMP1, and DNA staining, cells were fixed for 20 min with 4% parafomaldehyde/PBS, followed by permeabilization and blocking for 30 min with 0.05% saponin/5% FBS/PBS. For NMII and DNA staining, cells were fixed and permeabilized with 100% methanol for 10 min, followed by blocking for 30 min with 5% FBS/PBS. NMII was labeled using rabbit polyclonal serum directed against formalin-fixed bacteria and goat anti-rabbit Alexa Fluor 594 IgG (Thermo Fisher Scientific). LAMP1 was labeled with rat antimouse LAMP1 (Santa Cruz Biotechnology) and goat anti-rat Alexa Fluor 488 IgG (Thermo Fisher Scientific). Coverslips were mounted using ProLong Gold containing 4',6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific) to visualize nuclei. Cells were viewed by confocal fluorescence microscopy using a Zeiss LSM 710 confocal fluorescence microscope. Images were acquired using ZEN imaging software (Carl Zeiss, Inc.).

The proteolytic activity of vacuoles harboring NMII in BMDM was assessed by degradation of DQ Green BSA. BMDM (1 x 10^4 cells per well) in an 8-well Ibidi dish (Ibidi, Verona, WI) were infected with NMII at an MOI of 100. At 3 days post-infection, cells were incubated for 4 h in culture medium containing DQ Green BSA (50 μg/ml; Thermo Fisher Scientific) and Hoechst (20 μM). Live cells were imaged by confocal fluorescence microscopy using a PerkinElmer UltraView spinning disc confocal system connected to a Nikon Eclipse Ti-E inverted microscope with a LiveCell stage top incubator. Images were acquired using an Andor iXon Ultra EMCCD camera (Andor Technology, Inc., Belfast, United Kingdom) and NIS-Elements imaging software (Nikon Instruments, Inc.). All images were processed with ImageJ software written by W. S. Rasband at the U. S. National Institutes of Health, Bethesda, MD, and available from (https://imagej.nih.gov/ij/).
Ethics statement animal care and use

All experiments were performed in the Association for Assessment and Accreditation of Laboratory Animal Care-accredited Rocky Mountain Laboratories Animal Facility.

This study (ASP #2016–058) was approved by the Rocky Mountain Laboratories Institutional Animal Care and Use Committee, National Institute of Allergy and Infectious Disease, National Institutes of Health.

Results

NMII grows robustly in degradative, lysosome-like vacuoles of C57BL/6J BMDM differentiated with rmM-CSF

Previous studies using C57BL/6 BMDM differentiated with L-929 cell-conditioned medium show a severe growth restriction of NMII [25, 27, 30–35]. We therefore tested NMII growth in BMDM differentiated with rmM-CSF because this recombinant growth factor is recommended for experimental reproducibility [44]. BMDM were infected with NMII at MOIs of 0.1 and 10, and bacterial growth was monitored daily for 6 days by qPCR of GE. Roughly 3 log increases in NMII GE were observed over the infection time course (Fig 1A). By immunofluorescence microscopy, increases in genome numbers correlated with proliferation of C. burnetii within macrophages (Fig 1B). These micrographs also demonstrated initial infection efficiencies near 100%. As a control, we also infected BMDM differentiated with L-929 cell-conditioned medium. At 5 days post-infection, large Coxiella-containing vacuoles were evident in macrophages treated with rmM-CSF, but not L-929 cell-conditioned medium (S1 Fig).

Cumulative data from several cell culture model systems indicate that C. burnetii replicates in vacuoles with lysosomal characteristics [4]. To evaluate the nature of vacuoles harboring replicating NMII in C57BL/6J BMDM, infected cells were stained by immunofluorescence for LAMP1 or loaded with DQ Green BSA, a fluorogenic substrate where fluorescence is quenched until hydrolysis by lysosomal proteases [3]. Large and spacious vacuoles containing abundant NMII were clearly labeled with LAMP1 in BMDMs infected for 3 days (Fig 2A). Coxiella-containing vacuoles also exhibited pronounced labeling with DQ Green BSA, confirming their lysosomal nature (Fig 2B).

C57BL/6J BMDM infected by NMII lack defined polarization

Because macrophage activation status is associated with restriction of infection by bacterial pathogens, including C. burnetii [17], we examined the expression of M1/M2 polarization markers [16, 44] by flow cytometry. Live, mock infected BMDM (F4/80^+ CD11b^+), showed no appreciable expression of the M1 and M2 markers CD38 and early growth response protein 2 (Egr2), respectively (Fig 3A and 3B). Infection by NMII for 3 days did not change this M0 (non-polarized) phenotype (Fig 3A and 3B). Similar results were obtained at 1 day post-infection (data not shown). Infected and uninfected BMDM treated with LPS/IFNγ and IL-4 showed pronounced induction of CD38 and Egr2, respectively, thereby demonstrating appropriate M1 and M2 responses, respectively, to each stimulus (Fig 3B). We further assessed BMDM responses during infection by measuring levels of secreted TNF and production of nitric oxide (as measured by medium nitrite levels). In comparison to uninfected BMDM, NMII-infected cells produced slightly more TNF and nitric oxide (Fig 4A and 4B). Levels did not approach those associated with infected or uninfected BMDM treated with LPS, zymosan, or TNF (nitric oxide measurements only). Overall, these data demonstrate that uninfected and NMII-infected murine BMDM differentiated with rmM-CSF display an M0 phenotype. Moreover, infection does not inhibit M1 or M2 polarization in the presence of appropriate stimuli.
Fig 1. NMII grows robustly in C57BL/6J BMDM differentiated with rmM-CSF. (A) BMDM in 24-well plates were infected with NMII at an MOI of 0.1 or 10. Bacterial growth was assessed by quantifying genomic equivalents (GE). Results are expressed as the means of three biological replicates from one experiment and are representative of three independent experiments. Error bars indicate the standard deviations of the means. (B) BMDM on coverslips in 24-well plates were infected with NMII at an MOI of 10. Cells were fixed immediately after infection (Day 0), and at 1 and 3 days post-infection. Cells were stained for NMII (green) and DNA (blue), and fluorescent images overlaid with the corresponding phase contrast image. Bar, 10 μm.

doi:10.1371/journal.pone.0173528.g001
Wild type and Nramp1-positive ER-Hoxb8 macrophages are permissive for NMII growth

Our data clearly show that primary BMDM from C57BL/6J mice can support robust growth of NMII. An important implication of this finding is that genetic determinants of host susceptibility to NMII infection can now be evaluated using the vast array of knock-in, transgenic, and knock-out mice available in a C57BL/6 genetic background [45]. However, use of primary BMDM as a model system requires time-consuming preparation protocols and maintenance of breeding colonies. We therefore examined whether macrophages obtained from bone marrow-derived myeloid progenitors of C57BL/6J mice immortalized with an estrogen-regulated Hoxb8 (ER-Hoxb8) oncogene could support NMII growth [42]. In this system, myeloid progenitors expressing ER-Hoxb8 are continually renewed when cultured in the presence of beta-estradiol. Removal of estrogen and culture in rmM-CSF results in differentiation of progenitors into macrophages [46]. ER-Hoxb8 macrophages supported approximately 2 logs of growth of NMII prior to entry into stationary phase (Fig 5A). Replication corresponded to cells exhibiting large NMII-filled vacuoles (Fig 5B).

We extended our evaluation of the ER-Hoxb8 system to macrophages derived from myeloid progenitors of natural resistance-associated macrophage protein 1 (Nramp1) C57BL/6J transgenic mice. Nramp1 is a phagosome-associated metal transporter that depletes pathogen-containing vacuoles of divalent metals, such as Fe^{2+} and Mn^{2+} [47]. This component of nutritional immunity [47, 48] can restrict infection by intracellular pathogens that reside in vacuoles of the endolysosomal system [49]. Wild type C57BL/6J mice have a Gly169Asp substitution that results in defective Nramp1 production [47]. Replication and vacuole formation by NMII in wild type and ER-Hoxb8 Nramp1^+ macrophages were indistinguishable.
Fig 3. Permissive C57BL/6J BMDM display an M0 phenotype. BMDM were mock infected or infected with NMII at an MOI of 10. At 56 h post-infection, cells were treated with medium (no stimulation), 100 ng/ml LPS, or 20 ng/ml IL4. Six h prior to treatment with LPS, cells were also treated with 20 ng/ml IFN-γ. Flow cytometry was conducted at 72 h post-infection. (A) Cells were gated on live CD11b+ F4/80+ cells with additional gating on infected cells based on NMII signal. (B) Expression of CD38 and early growth response protein 2 (Egr2), markers of classically activated (M1) and alternatively activated (M2) macrophages, respectively. Results are representative of three independent experiments. doi:10.1371/journal.pone.0173528.g003

Fig 4. NMII-infected C57BL/6J BMDM produce moderate amounts of TNF and nitric oxide. BMDM were infected with NMII at an MOI of 50. At 8 h post-infection, cells were mock treated or treated with 100 ng/ml LPS (TLR4 ligand), 10 μg/ml zymosan (TLR2 ligand), or 10 ng/ml TNF (nitrite assay only). Following an 18 h treatment, culture supernatants were assayed for TNF by using an ELISA kit (A) and nitric oxide by determining nitrite concentration with the Griess reagent (B). Results are expressed as the means of three biological replicates from one experiment and are representative of two independent experiments. Error bars indicate the standard deviations of the means. doi:10.1371/journal.pone.0173528.g004
Fig 5. Wild type and Nramp1-positive ER-Hoxb8 macrophages are permissive for NMII growth. (A) Bone marrow-derived myeloid progenitors from wild type and C57BL/6J Nramp1+ mice were immortalized with an estrogen-regulated Hoxb8 (ER-Hoxb8) oncogene. Macrophages were derived from immortalized progenitors using M-CSF and infected with NMII at an MOI of 10. Approximately 2 logs of NMII growth, based on genome equivalents (GE), was observed in both C57BL/6J and C57BL/6J ER-Hoxb8 Nramp1+ macrophages over a 6 day time course. Results are expressed as the means of three biological replicates from one experiment and are representative of two independent experiments. Error bars indicate the standard deviations of the means. (B) Confocal fluorescence micrographs of ER-Hoxb8 micrographs showing large vacuoles harboring NMII (red) in both cell types at 3 days post-infection. DNA is stained with DAPI (blue). Bar, 10 μm. (C) Primary BMDM from wild type and C57BL/6J Nramp1+ mice differentiated with rmM-CSF were infected with NMII at an MOI of 0.1. Approximately 2 logs of NMII growth, based on genome equivalents (GE), was achieved at early stationary phase (3 days post-infection) in both cell types. (D) Primary BMDM from wild type and C57BL/6J Nramp1+ mice differentiated with rmM-CSF were infected with Salmo nella enterica serovar Typhimurium at an MOI of 5. Colony forming units (CFUs), representing intracellular bacteria, were enumerated at 1, 2, and 10 h post-infection by plating macrophage lysates on LB-agar plates. Significantly less CFU were recovered from Nramp1+ macrophages than from wild type macrophages at 10 h post-infection (asterisks, *p* < 0.01). Results are expressed as the means of three biological replicates from one experiment and are representative of two independent experiments. Error bars indicate the standard deviations of the means.

doi:10.1371/journal.pone.0173528.g005

(Fig 5A and 5B), suggesting Nramp-mediated metal depletion of the CCV does not negatively impact NMII growth. To validate our results with ER-Hoxb8 macrophages, we infected primary BMDM from wild type and C57BL/6J Nramp1+ mice differentiated with rmM-CSF with NMII and Salmonella enterica serovar Typhimurium. In agreement with ER-Hoxb8 macrophage results, no defect in NMII growth was detected in Nramp1+ primary BMDM relative to wild type macrophages (Fig 5C). In contrast, and in keeping with several published studies showing an in vivo role for Nramp1 in controlling Salmonella infection [41, 50–52], a significant decline in recoverable CFUs was detected from 6 to 10 h post-infection in Nramp1+ BMDM relative to wild type macrophages (Fig 5D).
Discussion

Depending on the strain of origin, primary murine BMDM have been previously reported to be moderately to markedly restrictive for NMII growth [25, 27, 29–34]. The biological basis of this behavior has been investigated in detail using highly restrictive BMDM from C57BL/6 mice. A working model attributes restriction of NMII to increased PAMP exposure that elicits production of inhibitory amounts of TNF and nitric oxide [23, 25, 27, 30–34]. Indeed, Bradley et al. [27] recently elucidated the importance of TNF by showing infection induces production of the cytokine, and that growth permissiveness of Tnf−/− macrophages is reversed by adding recombinant TNF or medium from infected C57BL/6 BMDM cultures. Furthermore, infected Tnf−/− BMDM produce lower levels of nitric oxide than wild type cells, invoking a potential inhibitory role for this innate immune mediator. To our knowledge, conditioned medium from murine L-929 cell cultures has been exclusively used in published NMII BMDM infection studies as a source of M-CSF to differentiate bone marrow-derived myeloid progenitors into macrophages. Here, we show that bone marrow progenitors of C57BL/6J mice differentiated with rmM-CSF are highly permissive for NMII growth, a phenotype that correlates with the lack of defined M1/M2 polarization. Interestingly, using similar infection conditions and time points, culture supernatant levels of nitrite in our study and the Bradley et al. study [27] were roughly the same (~2 μM) while TNF levels were approximately 3 times higher in the latter. These results suggest nitric oxide may play a minor role in limiting growth of NMII under restrictive BMDM culture conditions while additional TNF-induced factors play more substantial roles. Furthermore, BMDM cultured with L-929 cell-conditioned medium versus rmM-CSF may be primed to produce more TNF that limits NMII growth via activation of downstream effectors.

The 6 day stationary phase growth yields (2 to 3 logs) of NMII in C57BL/6J BMDM are similar to other cell culture infection systems, such as Vero epithelial cells and THP-1 macrophages [43, 53–55]. Early stationary phase was consistently reached no later than 3 days post-infection; however, in some growth curves NMII grew with accelerated lag/log phase kinetics relative to other host cell systems [43, 53]. The modest curve-to-curve variability in early time point growth kinetics may be due to several parameters including method of infection (e.g., centrifugation of inoculum or not), stock viability, DNA yield, inherent variability in qPCR (especially at early time points with low DNA concentrations), and MOI. From axenic media studies, we know that NMII is capable of a generation time much shorter than 10 to 11 h measured in the Vero cell system (4.7 h in ACCM-2) [38, 43]. Infections at MOIs >1 also generally have abbreviated lag/log phases, which we attribute to homotypic fusion of multiple Coxiella-containing vacuoles, a process that accelerates development of a replication-competent niche. Our infection procedure incorporated a centrifugation step, which aids internalization.

Indeed, an infection efficiency approaching 100% was achieved using an MOI of 10. Another factor potentially contributing to shortened lag phase is faster acidification of the NMII vacuole in BMDM than epithelial cells. A pH of approximately 5 is required for vigorous metabolic activation of C. burnetii and commencement of replication [56]. Indeed, Newton and co-workers [35] demonstrated translocation of NMII effector proteins as early as 1 h post-infection in BMDM as compared to 8 h post-infection in HeLa cells. Effector translocation is an energy requiring process and a predicted signature of metabolic activation [53].

Methods used to isolate, cultivate, and infect BMDM can dramatically affect their polarization state and permissiveness for microbial infection [44]. Growth parameters including the method of bone marrow processing, cell density, culture conditions, and media supplements all impact macrophage development [44, 57]. Conditioned medium from murine L-929 cell cultures is commonly used as a source of M-CSF to differentiate bone marrow-derived
myeloid progenitors into macrophages. However, variation in M-CSF levels in conditioned medium and the presence of type I interferons can affect macrophage responses to invading pathogens [44, 58]. To achieve reproducibility in BMDM experiments between different laboratories, differentiation of progenitors with endotoxin-free, rmM-CSF is now the accepted experimental standard [44]. Moreover, a detailed description of methodology is also recommended [44].

Interestingly, a recent study by Fernandes et al. [34] demonstrated that alveolar macrophages from C57BL/6 mice support growth of NMII with 2 logs of replication achieved at 12 days post-infection. Growth permissiveness in fully differentiated alveolar macrophages is attributed to a pronounced M2 polarization as compared to the M1 polarization of control BMDMs that were differentiated from monocytes with L-929 cell-conditioned medium. In general, alveolar macrophages are considered less pro-inflammatory than other tissue-resident macrophages, a property that enables environmental sampling without damaging immune responses [59]. Although the NMII growth yield per macrophage is roughly the same between the alveolar macrophages described by Fernandes et al. [34] and the BMDM of this report, bone marrow yields approximately 100-fold more macrophages than lungs (7 x 10⁷ versus 4 x 10⁵ per mouse, respectively), which greatly facilitates functional assays [60]. Nonetheless, alveolar macrophages are the initial target cell of aerosol-transmitted C. burnetii and consequently may constitute a more physiologically relevant ex vivo model system [61].

Nramp1 expression is associated with reduced animal model pathogenesis in the context of infection by Salmonella, Leishmania, and some species of Mycobacteria [50, 62]. Consistent with in vivo studies [41, 50–52], here we demonstrated that BMDM from C57BL/6 Nramp1+ knock-in mice more readily kill Salmonella Typhimurium than wild type macrophages. In contrast, NMII shows no growth deficiency in Nramp1+ primary BMDM or immortalized ER-Hoxb8 macrophages derived from C57BL/6J mice, suggesting Nramp1 removal of metal ions from the CCV does not have an inhibitory effect, at least during in vitro growth. Our results do not discount a protective role for Nramp1 during animal infection. Indeed, patients with post-Q fever fatigue syndrome show an increased frequency of allelic variants of Nramp1 [63]. Conversely, there is no correlation between the expression of Nramp1 and the sensitivity of various inbred mouse strains to C. burnetii infection [64]. Several bacterial pathogens express Nramp1 homologs termed MntH that may compete for metal ions depleted by Nramp1 [49]. However, C. burnetii does not encode an MntH protein [65]. In fact, the pathogen has few iron acquisition systems, one of which is the metal binding lipoprotein LimB [66]. Taken together with a small Fur regulon and enhanced growth in low iron environments, Briggs et al. [67] suggested that C. burnetii has a low iron requirement and that iron may be actually detrimental to intracellular growth of C. burnetii by promoting Fenton chemistry that produces damaging hydroxyl radicals [67].

In summary, our results show primary macrophages from wild type and genetically altered C57BL/6J mice can be used to define host-pathogen interactions that promote productive infection by attenuated phase II C. burnetii.

Supporting information
S1 Fig. C57BL/6J BMDM differentiated with L-929 cell-conditioned medium are less permissive for NMII growth than cells differentiated with rmM-CSF. BMDM infected for 5 days (MOI = 10) were fixed and stained by immunofluorescence for NMII (red). Nuclei (blue) were stained with DAPI. Large Coxiella-containing vacuoles are evident in rmM-CSF, but not L-929 cell-conditioned medium treated cells. Bar, 5 μm.

(PDF)
Acknowledgments
We thank Aaron Carmody for assistance with flow cytometry and Anita Mora for graphic support.

This work was supported by funding from the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (RAH)

Author Contributions
Conceptualization: DCC CML SJR LM RAH.
Formal analysis: DCC CML SJR PAB HEM LM TS RAH.
Funding acquisition: RAH.
Investigation: DCC CML SJR JGS LM HEM CLL PAB TS.
Methodology: DCC CML SJR JGS LM HEM CLL PAB.
Supervision: RAH.
Validation: DCC CML SJR RAH.
Visualization: DCC CML SJR JGS LM HEM CLL PAB.
Writing – original draft: DCC SJR RAH.
Writing – review & editing: RAH CLL HEM TS.

References
1. Angelakis E, Raoult D. Q Fever. Vet Microbiol. 2010; 140(3–4):297–309. Epub 2009/10/31. doi: 10.1016/j.vetmic.2009.07.016 PMID: 19875249
2. Tigertt WD, Benenson AS, Gochenour WS. Airborne Q fever. Bacteriol Rev. 1961; 25:285–93. PMID: 13921201
3. Howe D, Shannon JG, Winfree S, Dorward DW, Heinzhen RA. Coxiella burnetii phase I and II variants replicate with similar kinetics in degradative phagolysosome-like compartments of human macrophages. Infect Immun. 2010; 78(8):3465–74. Epub 2010/06/03. doi: 10.1128/IAI.00406-10 PMID: 20515926
4. Larson CL, Martinez E, Beare PA, Jeffrey B, Heinzhen RA, Bonazzi M. Right on Q: genetics begin to unravel Coxiella burnetii host cell interactions. Future microbiology. 2016; 11:919–39. doi: 10.2217/fmb-2016-0044 PMID: 27418426
5. Price JV, Vance RE. The macrophage paradox. Immunity. 2014; 41(5):685–93. doi: 10.1016/j.immuni.2014.10.015 PMID: 25517611
6. Chow SH, Deo P, Naderer T. Macrophage cell death in microbial infections. Cell Microbiol. 2016; 18(4):466–74. doi: 10.1111/cmi.12573 PMID: 26833712
7. Swanson MS. Autophagy: eating for good health. J Immunol. 2006; 177(8):4945–51. Epub 2006/10/04. PMID: 17015674
8. Romano PS, Gutierrez MG, Beron W, Rabinovitch M, Colombo MI. The autophagic pathway is actively modulated by phase II Coxiella burnetii to efficiently replicate in the host cell. Cell Microbiol. 2007; 9(4):891–909. doi: 10.1111/j.1462-5822.2006.00838.x PMID: 17087732
9. Winchell CG, Graham JG, Kurten RC, Voth DE. Coxiella burnetii type IV secretion-dependent recruitment of macrophage autophagosomes. Infect Immun. 2014; 82(6):2229–38. doi: 10.1128/IAI.01236-13 PMID: 24643534
10. Newton HJ, Kohler LJ, McDonough JA, Temoche-Diaz M, Crabill E, Hartland EL, et al. A screen of Coxiella burnetii mutants reveals important roles for Dot/Icm effectors and host autophagy in vacuole biogenesis. PLoS pathogens. 2014; 10(7):e1004286. doi: 10.1371/journal.ppat.1004286 PMID: 25080348
11. Martinez E, Allombert J, Cantel F, Lakhani A, Yandrapalli N, Neyret A, et al. Coxiella burnetii effector CvpB modulates phosphoinositide metabolism for optimal vacuole development. Proc Natl Acad Sci USA. 2016; 113(23):E3260–E9. doi: 10.1073/pnas.1522811113 PMID: 27226300
12. Luhrmann A, Nogueira CV, Carey KL, Roy CR. Inhibition of pathogen-induced apoptosis by a Coxiella burnetii type IV effector protein. Proc Natl Acad Sci USA. 2010; 107(44):18997–9001. Epub 2010/10/15. doi: 10.1073/pnas.1004103107 PMID: 20944063

13. Klingenbeck L, Eckart RA, Berens C, Luhrmann A. The Coxiella burnetii type IV secretion system substrate CaeB inhibits intrinsic apoptosis at the mitochondrial level. Cell Microbiol. 2013; 15(4):675–87. doi: 10.1111/cmi.12066 PMID: 23126667

14. Cunha LD, Ribeiro JM, Fernandes TD, Massis LM, Khoo CA, Moffatt JH, et al. Inhibition of inflammation by some activation by Coxiella burnetii type IV secretion system effector IcaA. Nat Commun. 2015; 6:10205. doi: 10.1038/ncomms10205 PMID: 26687278

15. Diacovich L, Gorvel JP. Bacterial manipulation of innate immunity to promote infection. Nat Rev Microbiol. 2010; 8(2):117–28. doi: 10.1038/nrmicro2295 PMID: 20075926

16. Beare PA, Samuel JE, Howe D, Virtaneva K, Porcella SF, Heinzen RA. Lack of dendritic cell maturation following infection by Coxiella burnetii synthesizing different lipopolysaccharide chemotypes. Ann N Y Acad Sci. 2005; 1063:154–60. doi: 10.1196/annals.1355.024 PMID: 16481507

17. Toman R, Skultety L. Structural study on a lipopolysaccharide from Coxiella burnetii strain Nine Mile in avirulent phase II. Carbohydr Res. 1996; 283:175–85. PMID: 8901269

18. Shannon JG, Howe D, Heinzen RA. Virulent Coxiella burnetii does not activate human dendritic cells: role of lipopolysaccharide as a shielding molecule. Proc Natl Acad Sci USA. 2005; 102(24):8722–7. doi: 10.1073/pnas.0501863102 PMID: 15939879

19. Shannon JG, Howe D, Heinzen RA. Lack of dendritic cell maturation following infection by Coxiella burnetii synthesizing different lipopolysaccharide chemotypes. Proc Natl Acad Sci USA. 1998; 95:359–65. PMID: 9988339

20. Hackstadt T, Peacock MG, Hitchcock PJ, Cole RL. Lipopolysaccharide variation in Coxiella burnetii: intraspecies heterogeneity in structure and antigenicity. Infect Immun. 1985; 48:359–65. PMID: 2301889

21. Beare PA, Samuel JE, Howe D, Virtaneva K, Porcella SF, Heinzen RA. Genetic diversity of the Q fever agent, Coxiella burnetii, assessed by microarray-based whole-genome comparisons. J Bacteriol. 2006; 188(7):2309–24. doi: 10.1128/JB.188.7.2309-2324.2006 PMID: 16547017

22. Tomàn R, Skultét L. Structural study on a lipopolysaccharide from Coxiella burnetii strain Nine Mile in avirulent phase II. Carbohydr Res. 1996; 283:175–85. PMID: 8901269

23. Ghigo E, Colombo MI, Heinzen RA. The Coxiella burnetii parasitophorous vacuole. Adv Exp Med Biol. 2012; 746:141–69. Epub 2012/06/20. doi: 10.1007/978-94-007-4315-1_8 PMID: 22711631

24. Hackstadt T. Steric hindrance of antibody binding to surface proteins of Coxiella burnetii by phase I lipopolysaccharide. Infect Immun. 1988; 56(4):802–7. PMID: 3346073

25. Zamboni DS, Campos MA, Torrecillas AC, Kiss K, Samuel JE, Golenbock DT, et al. Inhibition of pathogen-induced apoptosis by CaeB inhibits intrinsic apoptosis at the mitochondrial level. Cell Microbiol. 2013; 15(4):675–87. doi: 10.1111/cmi.12066 PMID: 23126667

26. Shannon JG, Heinzen RA. Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii. Immunol Res. 2009; 43(1–3):138–48. Epub 2008/09/25. doi: 10.1007/s12026-008-8059-4 PMID: 18813881

27. Bradley WP, Boyer MA, Nguyen HT, Birdwell LD, Yu J, Ribeiro JM, et al. Primary role for Toll-like receptor-driven tumor necrosis factor rather than cytosolic immune detection in restricting Coxiella burnetii phase II replication within mouse macrophages. Infect Immun. 2016; 84(4):998–1015. doi: 10.1128/IAI.01536-15 PMID: 26787725

28. Graham JG, MacDonald LJ, Hussain SK, Sharma UM, Kurten RC, Voth DE. Virulent Coxiella burnetii pathotypes productively infect primary human alveolar macrophages. Cell Microbiol. 2013; 15(6):1012–25. Epub 2013/01/03. doi: 10.1111/cmi.12096 PMID: 23279051

29. Sauer JD, Shannon JG, Howe D, Hayes SF, Swanson MS, Heinzen RA. Specificity of Legionella pneumophila and Coxiella burnetii vacuoles and versatility of Legionella pneumophila revealed by coinfection. Infect Immun. 2005; 73(8):4494–504. doi: 10.1128/IAI.73.8.4494-4504.2005 PMID: 16040960

30. Zamboni DS. Genetic control of natural resistance of mouse macrophages to Coxiella burnetii infection in vitro: macroparasites from restricted strains control parasitophorous vacuole maturation. Infect Immun. 2004; 72(4):2395–9. doi: 10.1128/IAI.72.4.2395-2399.2004 PMID: 15039367

31. Zamboni DS, Rabinovitch M. Phagocytosis of apoptotic cells increases the susceptibility of macrophages to infection with Coxiella burnetii Phase II through down-modulation of nitric oxide production. Infect Immun. 2004; 72(4):2075–80. doi: 10.1128/IAI.72.4.2075-2080.2004 PMID: 15039329

32. Zamboni DS, Rabinovitch M. Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages. Infect Immun. 2003; 71(3):1225–33. doi: 10.1128/IAI.71.3.1225-1233.2003 PMID: 12595436
33. Barry AO, Boucherit N, Mottola G, Vadovic P, Trouplin V, Soubeyran P, et al. Impaired stimulation of p38alpha-MAPK/Vps41-HOPS by LPS from pathogenic *Coxiella burnetii* prevents trafficking to microbial phagolysosomes. Cell Host Microbe. 2012; 12(6):751–63. doi: 10.1016/j.chom.2012.10.015 PMID: 2345320

34. Fernandes TD, Cunha LD, Ribeiro JM, Massis LM, Lima-Junior DS, Newton HJ, et al. Murine alveolar macrophages are highly susceptible to replication of *Coxiella burnetii* phase II in vitro. Infect Immun. 2016; 84(9):2439–48. doi: 10.1128/AI.00411-16 PMID: 27297388

35. Newton HJ, McDonough JA, Roy CR. Effector protein translocation by the *Coxiella burnetii* Dot/Icm type IV secretion system requires endocytic maturation of the pathogen-occupied vacuole. PLoS One. 2013; 8(1):e54566. Epub 2013/01/26. doi: 10.1371/journal.pone.0054566 PMID: 23349930

36. Ochoa-Reparaz J, Sentissi J, Trunkle T, Riccardi C, Pascual DW. Attenuated *Coxiella burnetii* phase II causes a febrile response in gamma interferon knockout and Toll-like receptor 2 knockout mice and protects against reinfection. Infect Immun. 2007; 75(12):5845–58. doi: 10.1128/IAI.00901-07 PMID: 17893129

37. Howe D, Barrows LF, Lindstrom NM, Heinzen RA. Nitric oxide inhibits *Coxiella burnetii* replication and parasitophorous vacuole maturation. Infect Immun. 2002; 70(9):5140–7. doi: 10.1128/IAI.70.9.5140-5147.2002 PMID: 12183564

38. Omisland A, Beare PA, Hill J, Cockrell DC, Howe D, Hansen B, et al. Isolation from animal tissue and genetic transformation of *Coxiella burnetii* are facilitated by an improved axenic growth medium. Appl Environ Microbiol. 2011; 77:3720–5. Epub 2011/04/12. doi: 10.1128/AEM.02826-10 PMID: 21478315

39. Lathrop SK, Binder KA, Starr T, Cooper KG, Chong A, Carmody AB, et al. Replication of *Salmonella enterica* serovar Typhimurium in human monocyte-derived macrophages. PLoS One. 2015; 83(7):2661–71. doi: 10.1128/ AJE.0033-15 PMID: 25895967

40. Crane DD, Ireland R, Alinger JB, Small P, Bosio CM. Lipids derived from virulent *Francisella tularensis* broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor alpha. Clin Vaccine Immunol. 2013; 20(10):1531–40. doi: 10.1128/CVI.00319-13 PMID: 23925684

41. Govoni G, Vidal S, Gauthier S, Skamene E, Malo D, Gros P. The Bcg/Ity/Lsh locus: genetic transfer of resistance to infections in C57BL/6J mice transgenic for the Nramp1 Gly169 allele. Infect Immun. 1996; 64(8):2823–9. PMID: 8757814

42. Wang GG, Calvo KR, Pasillas MP, Sykes DB, Hacker H, Kamps MP. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat Methods. 2006; 3(4):287–93. doi: 10.1038/nmeth865 PMID: 16554834

43. Coleman SA, Fischer ER, Howe D, Mead DJ, Heinzen RA. Temporal analysis of *Coxiella burnetii* morphological differentiation. J Bacteriol. 2004; 186(21):7344–52. doi: 10.1128/JB.186.21.7344-7352.2004 PMID: 15489446

44. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014; 41(1):14–20. doi: 10.1016/j.immuni.2014.06.008 PMID: 25035950

45. Mekada K, Abe K, Murakami A, Nakamura S, Nakata H, Moriwaki K, et al. Genetic differences among C57BL/6 substrains. Exp Anim. 2009; 58(2):141–9. PMID: 19448337

46. Rosas M, Osorio F, Robinson MJ, Davies LC, Dierkes N, Jones SA, et al. Hoxb8 conditionally immortalised macrophage lines model inflammatory mononuclear cells with important similarity to dendritic cells. Eur J Immunol. 2011; 41(2):356–65. doi: 10.1002/eji.201040962 PMID: 21268006

47. Wessling-Resnick M. Nramp1 and other transporters involved in metal withholding during Infection. J Biol Chem. 2015; 290(31):18984–90. doi: 10.1074/jbc.R115.643973 PMID: 26055722

48. Appelberg R. Macrophage nutrient antimicrobial mechanisms. J Leukoc Biol. 2006; 79(6):1117–28. doi: 10.1189/jlb.0206079 PMID: 16603567

49. Forbes JR, Gros P. Divalent-metal transport by NRAMP proteins at the interface of host-pathogen interactions. Trends Microbiol. 2001; 9(8):397–403. PMID: 11514223

50. Vidal S, Tremblay ML, Govoni G, Gauthier S, Sebastiani G, Malo D, et al. The *Ity/Lsh/Bcg* locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J Exp Med. 1995; 182(3):655–66. PMID: 7650477

51. Loomis WP, Johnson ML, Brasfield A, Bianc MP, Yi J, Miller SI, et al. Temporal and anatomical host resistance to chronic Salmonella infection is quantitatively dictated by Nramp1 and influenced by host genetic background. PLoS One. 2014; 9(10):e111763. doi: 10.1371/journal.pone.0111763 PMID: 25350495
52. Brown DE, Libby SJ, Moreland SM, McCoy MW, Brabb T, Stepanek A, et al. *Salmonella enterica* causes more severe inflammatory disease in C57/BL6 Nramp1G169 mice than Sv129S6 mice. Vet Pathol. 2013; 50(5):867–76. doi: 10.1177/0300985813478213 PMID: 23446432

53. Beare PA, Gilk SD, Larson CL, Hill J, Stead CM, Omsland A, et al. Dot/Icm type IVB secretion system requirements for *Coxiella burnetii* growth in human macrophages. MBio. 2011; 2(4):e00175–11. Epub 2011/08/25. doi: 10.1128/mBio.00175-11 PMID: 21862628

54. Beare PA, Sandoz KM, Larson CL, Howe D, Kronmiller B, Heinzen RA. Essential role for the response regulator PmrA in *Coxiella burnetii* type 4B secretion and colonization of mammalian host cells. J Bacteriol. 2014; 196(11):1925–40. Epub 2014/03/13. doi: 10.1128/JB.01532-14 PMID: 24610709

55. Larson CL, Beare PA, Voth DE, Howe D, Cockrell DC, Bastidas RJ, et al. *Coxiella burnetii* effector proteins that localize to the parasitophorous vacuole membrane promote intracellular replication. Infect Immun. 2015; 83(2):661–70. Epub 2014/11/26. doi: 10.1128/IAI.02763-14 PMID: 25422265

56. Hackstadt T, Williams JC. Biochemical stratagem for obligate parasitism of eukaryotic cells by *Coxiella burnetii*. Proc Natl Acad Sci USA. 1981; 78(5):3240–4. PMID: 6942430

57. Lee CM, Hu J. Cell density during differentiation can alter the phenotype of bone marrow-derived macrophages. Cell Biosci. 2013; 3:30. doi: 10.1186/2045-3701-3-30 PMID: 23895502

58. Warren MK, Vogel SN. Bone marrow-derived macrophages: development and regulation of differentiation markers by colony-stimulating factor and interferons. J Immunol. 1985; 134(2):982–9. PMID: 2578168

59. Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol. 2014; 14(2):81–93. doi: 10.1038/nri3600 PMID: 24445666

60. Goncalves R, Mosser DM. The isolation and characterization of muring macrophages. Curr Protoc Immun. 2015; 111:14.1.1-.1.6.

61. Stein A, Louvau C, Lepidi H, Ricci F, Baylou P, Davoust B, et al. Q fever pneumonia: virulence of *Coxiella burnetii* pathogens in a murine model of aerosol infection. Infect Immun. 2005; 73(4):2469–77. doi: 10.1128/IAI.73.4.2469-2477.2005 PMID: 15784593

62. Govoni G, Canonne-Hergaux F, Pfeifer CG, Marcus SL, Mills SD, Hackam DJ, et al. Functional expression of Nramp1 in vitro in the murine macrophage cell line RAW264.7. Infect Immun. 1999; 67(5):2225–32. PMID: 10225878

63. Helbig KJ, Heatley SL, Harris RJ, Mulligan CG, Bardy PG, Marmion BP. Variation in immune response genes and chronic Q fever: Concepts: preliminary test with post-Q fever fatigue syndrome. Genes Immun. 2003; 4(1):82–5. doi: 10.1038/sj.gene.6363912 PMID: 12595908

64. Scott GH, Williams JC, Stephenson EH. Animal models in Q fever: pathological responses of inbred mice to phase I *Coxiella burnetii*. J Gen Microbiol. 1987; 133( Pt 3):691–700.

65. Beare PA, Unsworth N, Andoh M, Voth DE, Omsland A, Gilk SD, et al. Comparative genomics reveal extensive transposon-mediated genomic plasticity and diversity among potential effector proteins within the genus *Coxiella*. Infect Immun. 2009; 77(2):642–56. doi: 10.1128/IAI.01141-08 PMID: 19047403

66. Battisti JM, Hicks LD, Minnick MF. A unique *Coxiella burnetii* lipoprotein involved in metal binding (LimB). Microbiology. 2011; 157:966–776. doi: 10.1099/mic.0.046649-0 PMID: 21212117

67. Briggs HL, Pul N, Seshadri R, Wilson MJ, Tersteeg C, Russell-Lodrigue KE, et al. Limited role for iron regulation in *Coxiella burnetii* pathogenesis. Infect Immun. 2008; 76(5):2189–201. doi: 10.1128/IAI.01608-07 PMID: 18316381